This pathogenetic correlation has been further confirmed by the identification of genetic variants predisposing to the development of MASLD (e.g., patatin-like phospholipase domain-containing protein 3 PNPLA3, transmembrane 6 superfamily member 2 TM6SF2, Apoliprotein B) which are also involved in hepatic cholesterol metabolism processes [28,29,30]. Here, TM6SF2 is linked to metabolic dysfunction-associated steatotic liver disease.